Intensity Therapeutics Inc (INTS)

$0.51 +0.05 (10.80%)
Market Cap 30.63M
Revenue (ttm) 0.00
Net Income (ttm) -16.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 8,401,101
Avg Vol 38,037,383
Day's Range N/A - N/A
Shares Out 60.07M
Stochastic %K 89%
Beta 3.58
Analysts Strong Sell
Price Target $3.25

Company Profile

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Industry: Biotechnology
Sector: Healthcare
Phone: 203 221 7381
Fax: 203 557 3023
Address:
1 Enterprise Drive, Suite 430, Shelton, United States
igniteyourpassion
igniteyourpassion Dec. 6 at 8:52 PM
$INTS https://seekingalpha.com/news/4528851-intensity-therapeutics-receives-180-day-nasdaq-extension-to-regain-compliance this should be well above 1+ coming week need some PR to get moving up
0 · Reply
MuzunguZanz
MuzunguZanz Dec. 6 at 7:22 PM
$INTS I would take $2 now for a BO. The SP might be worth much more 2 years from now. Maybe $5-$10-15?
0 · Reply
MTC_fool
MTC_fool Dec. 6 at 4:42 PM
$INTS : INTS should put in place a poison pill just in case of a hostile take over by big pharma!!
1 · Reply
malphius
malphius Dec. 6 at 3:48 PM
$INTS Look into the Invincible trials and early data. I had Grok do some scraping and It looks very positive. Looking cautiously forward to the two upcoming presentations
0 · Reply
malphius
malphius Dec. 6 at 12:59 AM
$INTS Loading
0 · Reply
goblin0213
goblin0213 Dec. 5 at 11:57 PM
$INTS My average price is $0.435 x 100,000 shares . Holding 🚀🚀🤑🙏
0 · Reply
SPYmyQQQ
SPYmyQQQ Dec. 5 at 11:48 PM
🎯 Target Hit 🏁 📨 From Nov 20, 2025 💊 $INTS 💵 Entry: $0.4288 ✅ Ext: $0.5008 💰 P/L: +16.79% 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
Emg123
Emg123 Dec. 5 at 10:14 PM
$INTS mark my words this will hit $1 mid week
1 · Reply
Zetergius
Zetergius Dec. 5 at 9:19 PM
$INTS so I’ve had nothing to say to the shorts on here except bad things like I hope you and your mother doesn’t get the type of cancer. This place is caring and you’re shorting it. But I will say now I would probably stop shorting this stock sooner than later. Cause y’all may need the medicine.
1 · Reply
Zetergius
Zetergius Dec. 5 at 9:05 PM
$INTS like I said halfway there 
1 · Reply
Latest News on INTS
Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Dec 5, 2025, 7:30 AM EST - 1 day ago

Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium

Dec 4, 2025, 7:47 AM EST - 2 days ago

Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium

Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 6, 2025, 4:02 PM EST - 4 weeks ago

Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Intensity Therapeutics, Inc. (INTS) Discusses eBioMedicine Paper Study Results and Underlying Technology Transcript

Oct 31, 2025, 1:36 PM EDT - 5 weeks ago

Intensity Therapeutics, Inc. (INTS) Discusses eBioMedicine Paper Study Results and Underlying Technology Transcript

Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock

Oct 31, 2025, 8:00 AM EDT - 5 weeks ago

Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock

Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal

Oct 30, 2025, 7:30 AM EDT - 5 weeks ago

Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal

Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update

Sep 10, 2025, 7:47 AM EDT - 3 months ago

Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update

Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 7:47 AM EDT - 3 months ago

Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Aug 12, 2025, 7:47 AM EDT - 4 months ago

Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Intensity (INTS) Q2 Net Loss Drops 50%

Aug 7, 2025, 4:57 PM EDT - 4 months ago

Intensity (INTS) Q2 Net Loss Drops 50%

Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 4:06 PM EDT - 4 months ago

Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025

Aug 4, 2025, 7:47 AM EDT - 4 months ago

Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025

Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)

Jun 30, 2025, 8:00 AM EDT - 5 months ago

Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)

Intensity Therapeutics, Inc. Announces Pricing of Public Offering

Jun 11, 2025, 11:46 PM EDT - 6 months ago

Intensity Therapeutics, Inc. Announces Pricing of Public Offering

Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Jun 11, 2025, 4:06 PM EDT - 6 months ago

Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study

Jun 11, 2025, 8:30 AM EDT - 6 months ago

Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

May 29, 2025, 8:00 AM EDT - 6 months ago

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon

May 28, 2025, 8:00 AM EDT - 6 months ago

Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon

Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025, 4:06 PM EDT - 7 months ago

Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France

May 6, 2025, 8:00 AM EDT - 7 months ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

Apr 25, 2025, 8:00 AM EDT - 8 months ago

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

Mar 13, 2025, 4:07 PM EDT - 9 months ago

Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

Jan 28, 2025, 8:00 AM EST - 11 months ago

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

Jan 10, 2025, 8:00 AM EST - 11 months ago

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Dec 12, 2024, 8:00 AM EST - 1 year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

Nov 21, 2024, 8:00 AM EST - 1 year ago

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

Nov 18, 2024, 8:00 AM EST - 1 year ago

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 4:06 PM EST - 1 year ago

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

Nov 8, 2024, 8:01 AM EST - 1 year ago

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)

Oct 31, 2024, 9:00 AM EDT - 1 year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)

Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 8, 2024, 4:19 PM EDT - 1 year ago

Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma

Jul 9, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

May 15, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

Intensity Therapeutics: A Bargain For A Late-Stage Company With A Remarkable Oncology Drug

May 14, 2024, 9:38 AM EDT - 1 year ago

Intensity Therapeutics: A Bargain For A Late-Stage Company With A Remarkable Oncology Drug

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

May 10, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 4:08 PM EDT - 1 year ago

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024

Apr 2, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024

Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 14, 2024, 4:09 PM EDT - 1 year ago

Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024

Mar 14, 2024, 8:00 AM EDT - 1 year ago

Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024

Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference

Feb 21, 2024, 8:01 AM EST - 1 year ago

Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference

Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program

Jan 3, 2024, 8:01 AM EST - 2 years ago

Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program

Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer

Dec 12, 2023, 8:01 AM EST - 2 years ago

Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS

Dec 8, 2023, 8:30 AM EST - 2 years ago

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS

Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium

Dec 1, 2023, 8:01 AM EST - 2 years ago

Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium

Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

Nov 13, 2023, 8:01 AM EST - 2 years ago

Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023

Nov 2, 2023, 7:01 AM EDT - 2 years ago

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023

Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma

Sep 7, 2023, 8:01 AM EDT - 2 years ago

Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma

Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 5, 2023, 8:01 AM EDT - 2 years ago

Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update

Aug 14, 2023, 7:01 AM EDT - 2 years ago

Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update

igniteyourpassion
igniteyourpassion Dec. 6 at 8:52 PM
$INTS https://seekingalpha.com/news/4528851-intensity-therapeutics-receives-180-day-nasdaq-extension-to-regain-compliance this should be well above 1+ coming week need some PR to get moving up
0 · Reply
MuzunguZanz
MuzunguZanz Dec. 6 at 7:22 PM
$INTS I would take $2 now for a BO. The SP might be worth much more 2 years from now. Maybe $5-$10-15?
0 · Reply
MTC_fool
MTC_fool Dec. 6 at 4:42 PM
$INTS : INTS should put in place a poison pill just in case of a hostile take over by big pharma!!
1 · Reply
malphius
malphius Dec. 6 at 3:48 PM
$INTS Look into the Invincible trials and early data. I had Grok do some scraping and It looks very positive. Looking cautiously forward to the two upcoming presentations
0 · Reply
malphius
malphius Dec. 6 at 12:59 AM
$INTS Loading
0 · Reply
goblin0213
goblin0213 Dec. 5 at 11:57 PM
$INTS My average price is $0.435 x 100,000 shares . Holding 🚀🚀🤑🙏
0 · Reply
SPYmyQQQ
SPYmyQQQ Dec. 5 at 11:48 PM
🎯 Target Hit 🏁 📨 From Nov 20, 2025 💊 $INTS 💵 Entry: $0.4288 ✅ Ext: $0.5008 💰 P/L: +16.79% 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
Emg123
Emg123 Dec. 5 at 10:14 PM
$INTS mark my words this will hit $1 mid week
1 · Reply
Zetergius
Zetergius Dec. 5 at 9:19 PM
$INTS so I’ve had nothing to say to the shorts on here except bad things like I hope you and your mother doesn’t get the type of cancer. This place is caring and you’re shorting it. But I will say now I would probably stop shorting this stock sooner than later. Cause y’all may need the medicine.
1 · Reply
Zetergius
Zetergius Dec. 5 at 9:05 PM
$INTS like I said halfway there 
1 · Reply
Pettechfl
Pettechfl Dec. 5 at 8:10 PM
$INTS wait for it, price spike soon
0 · Reply
Jimmyjabba
Jimmyjabba Dec. 5 at 8:01 PM
$INTS something cooking over here. Im in for 1k.
0 · Reply
topstockalerts
topstockalerts Dec. 5 at 7:46 PM
$INTS small caps continue to run..
0 · Reply
Dirt_Nasty_Trades
Dirt_Nasty_Trades Dec. 5 at 7:45 PM
$INTS BOOM!!! here it goes $TGL👀👆
1 · Reply
Catchmeifucan82
Catchmeifucan82 Dec. 5 at 7:38 PM
$INTS Nice. Has cash runway to first quarter 2027. Don't see that to often with stocks under $1.00. 🧐
1 · Reply
TNNSTrade
TNNSTrade Dec. 5 at 6:52 PM
$INTS setting up for a nice close above .50 - more updates on trials coming soon! 👀
0 · Reply
Zetergius
Zetergius Dec. 5 at 6:44 PM
$INTS  all we need is a dollar by June and we’re halfway there. Enjoy your weekend. Bears will mess with this some next week, and then knocked to jinx anything, but this may be off to the moon. And I never say that. Just my opinion.
1 · Reply
Zetergius
Zetergius Dec. 5 at 6:32 PM
$INTS I’m holding
1 · Reply
ChippyRiddler
ChippyRiddler Dec. 5 at 6:32 PM
$INTS
0 · Reply
IggieKooppa
IggieKooppa Dec. 5 at 6:20 PM
$INTS The Company now has until June 1, 2026 to meet the Minimum Bid Price Requirement set forth in Nasdaq Listing Rule 5550(a)(2).
0 · Reply
MuzunguZanz
MuzunguZanz Dec. 5 at 6:05 PM
$INTS This is a controlled appreciation in the SP. I am wondering what they have in mind in terms the fair SP value. I am sure we have the extension and maybe additional PR regarding next stage trials. A lot will unfurl in the next 2-3 weeks.
1 · Reply
Muffincrumbs
Muffincrumbs Dec. 5 at 5:47 PM
$INTS I bought 420 shares. It will surely tank...
2 · Reply